Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly.
Ebola virus
VP40
computational biology
mathematical modeling
phosphatidylserine
virus assembly
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
17
12
2021
revised:
02
05
2022
accepted:
04
05
2022
pubmed:
15
5
2022
medline:
27
7
2022
entrez:
14
5
2022
Statut:
ppublish
Résumé
Ebola virus (EBOV) infections continue to pose a global public health threat, with high mortality rates and sporadic outbreaks in Central and Western Africa. A quantitative understanding of the key processes driving EBOV assembly and budding could provide valuable insights to inform drug development. Here, we use a computational model to evaluate EBOV matrix assembly. Our model focuses on the assembly kinetics of VP40, the matrix protein in EBOV, and its interaction with phosphatidylserine (PS) in the host cell membrane. It has been shown that mammalian cells transfected with VP40-expressing plasmids are capable of producing virus-like particles (VLPs) that closely resemble EBOV virions. Previous studies have also shown that PS levels in the host cell membrane affects VP40 association with the plasma membrane inner leaflet and that lower membrane PS levels result in lower VLP production. Our computational findings indicate that PS may also have a direct influence on VP40 VLP assembly and budding, where a higher PS level will result in a higher VLP budding rate and filament dissociation rate. Our results further suggest that the assembly of VP40 filaments follow the nucleation-elongation theory, where initialization and oligomerization of VP40 are two distinct steps in the assembly process. Our findings advance the current understanding of VP40 VLP formation by identifying new possible mechanisms of PS influence on VP40 assembly. We propose that these mechanisms could inform treatment strategies targeting PS alone or in combination with other VP40 assembly steps.
Identifiants
pubmed: 35568195
pii: S0021-9258(22)00465-3
doi: 10.1016/j.jbc.2022.102025
pmc: PMC9218153
pii:
doi:
Substances chimiques
Phosphatidylserines
0
VP40 protein, virus
0
Viral Matrix Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102025Subventions
Organisme : NIAID NIH HHS
ID : R01 AI081077
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM075762
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001108
Pays : United States
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.
Références
Biophys J. 2012 Jun 6;102(11):2517-25
pubmed: 22713567
J Biol Chem. 2018 Mar 2;293(9):3335-3349
pubmed: 29348171
J Biol Chem. 1986 May 5;261(13):5784-9
pubmed: 3700372
J Virol. 2015 Sep;89(18):9440-53
pubmed: 26136573
Antiviral Res. 2016 Nov;135:62-73
pubmed: 27743917
J Am Soc Nephrol. 2015 Jan;26(1):31-7
pubmed: 25398785
Drugs. 2021 Jan;81(1):175-178
pubmed: 33432551
J Am Chem Soc. 2020 Jan 22;142(3):1367-1374
pubmed: 31867961
Elife. 2020 Oct 05;9:
pubmed: 33016878
PLoS One. 2012;7(1):e29608
pubmed: 22247782
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):27142-27150
pubmed: 31843887
N Engl J Med. 2019 Jul 25;381(4):373-383
pubmed: 31141654
N Engl J Med. 2014 Dec 18;371(25):2402-9
pubmed: 25390460
Biochem Biophys Res Commun. 2017 Nov 4;493(1):176-181
pubmed: 28917841
Infect Dis Poverty. 2015 Feb 24;4:13
pubmed: 25737782
Sci Rep. 2016 Nov 02;6:35762
pubmed: 27805006
N Engl J Med. 2016 Jan 7;374(1):23-32
pubmed: 26735991
PLoS Curr. 2014 Sep 02;6:
pubmed: 25642364
Biophys J. 2012 Nov 7;103(9):L41-3
pubmed: 23199932
Biochem Biophys Res Commun. 2020 Jun 25;527(2):387-392
pubmed: 32327259
J Biol Chem. 2013 Feb 22;288(8):5779-89
pubmed: 23297401
Clin Infect Dis. 2016 Nov 15;63(10):1288-1294
pubmed: 27553371
PLoS Med. 2016 Apr 19;13(4):e1001997
pubmed: 27093560
Front Microbiol. 2014 Jun 18;5:300
pubmed: 24995005
Cell Mol Life Sci. 2001 Dec;58(14):2069-84
pubmed: 11814057
EMBO Rep. 2022 Nov 7;23(11):e51709
pubmed: 36094794
PLoS Pathog. 2013;9(8):e1003561
pubmed: 23990783
J Proteome Res. 2009 Jan;8(1):104-12
pubmed: 18954100
MMWR Morb Mortal Wkly Rep. 2019 Dec 20;68(50):1162-1165
pubmed: 31856146
PLoS One. 2019 May 30;14(5):e0217559
pubmed: 31145752
Antiviral Res. 2014 May;105:17-21
pubmed: 24583123
PLoS Pathog. 2007 Jan;3(1):e9
pubmed: 17238286
Am J Nurs. 2021 Apr 1;121(4):22
pubmed: 33755619
Eur J Biochem. 1988 Dec 1;178(1):61-9
pubmed: 3203694
Curr Opin Cell Biol. 2003 Feb;15(1):111-7
pubmed: 12517712
J Virol. 2010 Jul;84(14):7053-63
pubmed: 20463076
Biophys J. 2013 May 7;104(9):1940-9
pubmed: 23663837
Sci Adv. 2018 Jan 10;4(1):e1701676
pubmed: 29349296
Protein Sci. 2016 Sep;25(9):1648-58
pubmed: 27328459
J Infect. 2017 Mar;74(3):302-309
pubmed: 27867062
Biophys Rev. 2018 Apr;10(2):527-534
pubmed: 29214606
Viruses. 2014 Oct 17;6(10):3837-54
pubmed: 25330123
Front Microbiol. 2015 Apr 09;6:257
pubmed: 25914675
PLoS One. 2016 Sep 09;11(9):e0162199
pubmed: 27611077
PLoS One. 2018 May 23;13(5):e0196402
pubmed: 29791461
Antiviral Res. 2019 Mar;163:179-184
pubmed: 30611774
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Mol Cell Biol. 2015 Nov 16;36(2):363-74
pubmed: 26572827
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
DNA Cell Biol. 2019 Feb;38(2):115-120
pubmed: 30615471
Sci Rep. 2017 Aug 21;7(1):8975
pubmed: 28827623
Lancet. 2003 Dec 13;362(9400):1953-8
pubmed: 14683653
J Biol Chem. 2012 Dec 21;287(52):43573-84
pubmed: 23124205
N Engl J Med. 2016 Oct 13;375(15):1448-1456
pubmed: 27732819
N Engl J Med. 2016 Jan 7;374(1):33-42
pubmed: 26735992
Expert Opin Ther Targets. 2014 Feb;18(2):115-20
pubmed: 24283270
Cell. 2013 Aug 15;154(4):763-74
pubmed: 23953110
Math Biosci. 1996 Nov;138(1):1-22
pubmed: 8942173
Trends Microbiol. 2007 Sep;15(9):408-16
pubmed: 17698361
Org Biomol Chem. 2003 Oct 21;1(20):3471-91
pubmed: 14599006
Sci Rep. 2016 Jan 12;6:19125
pubmed: 26753796
J Virol. 2019 Aug 28;93(18):
pubmed: 31243126
PLoS One. 2017 Feb 22;12(2):e0169255
pubmed: 28225767
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
PLoS Med. 2016 Mar 01;13(3):e1001967
pubmed: 26930627
Nat Rev Immunol. 2003 Aug;3(8):677-85
pubmed: 12974482
Front Microbiol. 2020 Apr 29;11:725
pubmed: 32411105
Sci Rep. 2015 Sep 08;5:13857
pubmed: 26347015
Biochim Biophys Acta Biomembr. 2017 Oct;1859(10):2012-2020
pubmed: 28711356
J Chem Phys. 2009 Jan 21;130(3):035102
pubmed: 19173542
Clin Infect Dis. 2015 Aug 15;61(4):496-502
pubmed: 25904375
Antiviral Res. 2017 Apr;140:95-105
pubmed: 28132865
Phys Chem Chem Phys. 2016 Oct 19;18(41):28409-28417
pubmed: 27757455
Biophys J. 2001 Sep;81(3):1805-22
pubmed: 11509390
Nat Med. 2008 Dec;14(12):1357-62
pubmed: 19029986
Crit Care Med. 2015 Oct;43(10):2066-75
pubmed: 26196353
Virol J. 2006 May 23;3:31
pubmed: 16719918
Nat Commun. 2018 Oct 1;9(1):4013
pubmed: 30275474
Eur J Med Chem. 2021 May 5;217:113381
pubmed: 33756124
J Virol. 2005 Feb;79(3):1898-905
pubmed: 15650213